Majority of Patients with Colorectal, Lung Cancer Believe Surgery Is Cure
the Cancer Therapy Advisor take:
Participants in this study included 3,954 patients who underwent surgery for lung (30.3%) or colorectal (69.7%) cancer between 2003 and 2005. These patients were identified from a population- and health system-based survey from across the United States.
Approximately 80.0% of patients with lung cancer and 89.7% with colorectal cancer reported that they believed surgical resection would cure their cancer.
Of patients with stage IV lung cancer, 57.4% also believed surgery would cure their disease, along with 79.8% of patients with stage IV colorectal cancer.
The belief of curative surgery was found to be higher among patients with colorectal cancer versus those with lung cancer (OR = 2.27).
Results showed that single, female patients with an advanced tumor stage and having a high number of comorbidities were less likely to have the belief that surgery would cure their cancer. Patients who communicated effectively with their physician and shared a role in decision-making with their physician (OR = 1.16) or family (OR = 1.17) had a higher perception that surgery would be a cure.
However, patients who did not have hands-on participation in decision-making and reported a physician-controlled (OR = 0.56) or family-controlled (OR = 0.72) approach were less likely to believe surgery would be curative.
The study suggests improvement be made in the patient-physician engagement and communication mechanism. Additionally, the authors recommend that barriers regarding the discussion of goals of care with patients diagnosed with cancer be addressed.
A majority of patients with lung and colorectal cancer reported perceptions that surgery would cure their cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas
- Managing Chemotherapy- and Radiation Therapy-Induced Nausea and Vomiting
- Can Oncolytic Viruses Improve Immunotherapies?
- Coffee and Cancer
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC
- Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC
- First-Line Pancreatic Cancer Treatment Varies Across Europe, But Aligns With ESMO Guideline
- Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma
- Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer
- Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer